The active form of
vitamin D(3),
1,25-dihydroxyvitamin D(3) [
1,25(OH)(2)D(3)], modulates proliferation and induces differentiation of many
cancer cells. A new class of analogs of
vitamin D(3) has been synthesized, having two side-chains attached to
carbon-20 (Gemini) and
deuterium substituted on one side-chain. We have examined six of these analogs for their ability to inhibit growth of
myeloid leukemia (HL-60), prostate (LNCaP, PC-3, DU145), lung (H520), colon (HT-29), and breast (MCF-7)
cancer cell lines. Dose-response clonogenic studies showed that all six analogs had greater antiproliferative activities against
cancer cells than
1,25(OH)(2)D(3). Although they had similar potency, the most active of these analogs was BXL-01-0120. BXL-01-0120 was 529-fold more potent than
1,25(OH)(2)D(3) in causing 50% clonal growth inhibition (ED(50)) of HL-60 cells. Pulse-exposure studies demonstrated that exposure to BXL-01-120 (10(-9)M, 48h) resulted in 85% clonal inhibition of HL-60 growth. BXL-01-0120 (10(-11)M, 4 days) induced the
differentiation marker, CD11b. Also, morphologically differentiation was more prominent compared to
1,25(OH)(2)D(3).
Annexin V assay showed that BXL-01-0120 (10(-10)M, 4 days) induced significantly (p<0.05) more apoptosis than
1,25(OH)(2)D(3). In summary, these analogs have a unique structure resulting in extremely potent inhibition of clonal proliferation of various types of
cancer cells, especially HL-60 cells.